NFE2L2 and prostate carcinoma: By contrast, low levels of Nrf2 expression were correlated with poor survival in patients with melanoma (p = 0.0341), kidney cancer (p = 0.0203), and prostate cancer (p = 0.00279) (Juan et al., 2014).